Kailera Therapeutics

Kailera Therapeutics is a pioneering force in Biotechnology Research, dedicated to developing innovative therapies for obesity and empowering individuals to transform their lives. Kailera Therapeutics is committed to advancing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies, designed to meet the evolving needs of those seeking effective weight management solutions.

At the forefront of their pipeline is KAI-9531 (HRS9531 in China), an injectable GLP-1/GIP receptor dual agonist, which has shown promising clinical trial results in obesity treatment in China. Kailera Therapeutics is also aggressively pursuing a diversified pipeline, exploring multiple mechanisms and routes of delivery to ensure comprehensive coverage in weight management.

Kailera Therapeutics' mission is clear: to develop next-generation weight management therapies that empower individuals to take control of their health and well-being. With locations in Waltham, MA, and San Diego, CA, Kailera Therapeutics is strategically positioned to drive advancements in obesity treatment. To the Manager of Kailera Therapeutics, we invite you to create a customized and exclusive company showcase and product listing on our platform to further enhance your market presence and connect with a broader audience.